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The human apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for 
Alzheimer’s disease (AD). The inheritance of ApoE4 predisposes one to 
develop AD in a gene-dose dependent manner, and its expression results in the 
earlier onset of the disease, greater accumulation of amyloid plaques and 
poorer memory performance in humans. Interestingly, the AD brain has been 
demonstrated to be at an insulin resistant state. To examine the effects of ApoE 
isoforms and brain insulin signaling in the presence of Aβ, and their resultant 
effects on memory, we created bigenic mice by crossing an ApoE knock-in 
mouse with a mutant human amyloid precursor protein (APP) mouse, and 
employed biochemical, electrophysiological and behavioral assessments in our 
in vivo and in vitro systems. Our results show an ApoE isoform dependent 
difference in binding preference to Aβ and the insulin receptor (IR), in both 
mice and post-mortem brain tissues. We also show that insulin signaling 
impairment in our ApoE4-APP mice is associated to the earlier onset of 
memory decline. In ApoE4 hippocampal neurons, insulin signaling dysfunction 
in the presence of Aβ prevented insertion of new AMPA receptors into the 
postsynaptic membrane. Taken together, our results show that ApoE isoform 
expression and insulin sensitivity can be an early biomarker for predicting 
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1.1 Alzheimer’s Disease (AD) 
Alzheimer’s Disease (AD) is a devastating neurodegenerative disease, 
characterized by the presence of extracellular deposits of amyloid plaques, and 
intracellular neurofibrillary tangles of hyperphosphorylated tau (Huang & 
Mucke, 2012; Mucke & Selkoe, 2012; Palop & Mucke, 2010; Selkoe, 2002; 
Wildsmith et al, 2013). The clinical manifestation of the disease usually starts 
with patients having benign complaints of forgetfulness, and as the disease 
progresses, atrophy of the brain occurs with substantial grey matter loss 
(Thompson et al, 2003). The progressive memory decline continues, and with 
time, patients lose their cognitive faculties, ultimately leading to dementia 
(Huang & Mucke, 2012; Palop & Mucke, 2010; Selkoe, 2002).  
 
1.1.1 Disease biology of AD 
The presence of extracellular amyloid plaques is one of the main defining 
characteristics of the disease. Amyloid plaques are composed of oligomerized 
amyloid β (Aβ) peptide monomers that have accumulated over time.  
 
Aβ is produced by the sequential cleavage of the amyloid precursor protein 
(APP). The gene encoding for APP is located on Chromosome 21. During 
protein translation, the APP holoprotein enters the endoplasmic reticulum (ER) 
and matures as it moves through the secretory pathway (Huang & Mucke, 
2012; Serrano-Pozo et al, 2011; Snyder et al, 1994; Stine et al, 2011; Yun et al, 
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2006). Once matured the APP is inserted into the cell membrane at the 
transmembrane domain, which occur between amino acids 709 and 714 
(Sisodia & St George-Hyslop, 2002). The C-terminus of the APP is 
intracellular, whereas the N-terminus of the protein faces the extracellular 
environment (Brettschneider et al, 2015; Chow et al, 2010; Huang & Mucke, 
2012; Serrano-Pozo et al, 2011). The transmembrane site of the APP is of 
utmost importance to the study of Aβ secretion as it contains several 
recognition sites for enzymatic cleavage. As the APP is a single-pass 
transmembrane protein, it is a substrate for intra-membranous proteases, such 
as the γ-secretase (Chow et al, 2010).  
 
The γ-secretase is an enzyme complex made up of four subunits, namely 
presenilin, nicastrin, aph-1, and pen-2, and it cleaves the APP at either position 
711 or 713 (Chow et al, 2010). Cleavage by γ-secretase alone does not yield 
Aβ monomers. The C-terminus of the APP can be cleaved by either α-
secretase or β-secretase (Chow et al, 2010).  
 
The APP is cleaved by α-secretase at amino acid residue position 687, which 
lies within the Aβ sequence (Chow et al, 2010; Zhang et al, 2012; Zhang et al, 
2011). When APP is cleaved by α-secretase, secreted APP α (sAPPα) is 
produced. While the exact function of sAPPα is uncertain, sAPPα has been 
shown to be neuroprotective. Some of its functions include the stabilization of 
resting membrane potential, promotion of neurite outgrowth and cell adhesion 
(Chow et al, 2010; Zhang et al, 2012; Zhang et al, 2011). As α-secretase 
cleaves across the Aβ sequence, subsequent cleavage of APP by γ-secretase 
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will not produce Aβ monomers. Following α-secretase cleavage, γ-secretase 
cleavage produces p3 and the APP intracellular domain (AICD) (Chow et al, 
2010; Ling et al, 2003; Nunan & Small, 2002; Zhang et al, 2012; Zhang et al, 
2011).  
 
On the other hand, β-secretase cleaves the APP at position 671. Subsequent 
cleavage by γ-secretase at either position 711 or 713 leads to the release of 
either Aβ40 or Aβ42 respectively (Chow et al, 2010; Ling et al, 2003; Mucke & 
Selkoe, 2012; Nunan & Small, 2002; Palop & Mucke, 2010; Selkoe, 2002; 
Zhang et al, 2012; Zhang et al, 2011). Aβ oligomers are neurotoxic. One of the 
current hypothesis for Aβ’s role in memory impairment in AD is that Aβ 
disrupts glutamatergic transmission and spine density, although the exact 
mechanism remains unclear. Moreover, Aβ also disrupts neuron networks by 
increasing spontaneous action potential firing and inward calcium currents. Aβ 
also intensifies neuronal death by activating microglia, mounting a chronic 
inflammatory response in the brain (Brettschneider et al, 2015; Chow et al, 
2010; Hiltunen et al, 2009; Huang & Mucke, 2012; Mucke et al, 2000; Mucke 
& Selkoe, 2012; Price et al, 2001; Selkoe, 2002; Snyder et al, 1994; Zhang et 
al, 2012; Zhang et al, 2011).  
 
Under normal circumstances, Aβ in the brain can be cleared by Apolipoprotein 
E (ApoE) (Bales et al, 2009; Mahley & Rall, 2000; Mahley et al, 2006). ApoE 
can bind to Aβ, which ferries it to lipoprotein receptors (LRP) lining the 
choroid plexus for clearance into the cerebrospinal fluid (CSF). This is 
supported by reports showing that Aβ levels in the CSF of normal patients are 
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always higher than that of AD cases (Huang & Mucke, 2012; Mahley & Rall, 
2000; Mahley et al, 2006; Palop & Mucke, 2010). However, under pathologic 
conditions, the production of Aβ species occurs faster than its clearance. If left 
unchecked, the continued accumulation of Aβ peptides forms oligomers and 
eventually, plaques. Some have hypothesized that Aβ oligomers assert its 
deleterious effects in the brain while on its way to developing into plaques 
(Mahley & Rall, 2000; Mahley et al, 2006). Taken together, while Aβ is central 
to AD pathology, it also makes AD a multi-faceted disease. Apart from 
inducing cell death, Aβ peptides disrupt neuronal network synchrony, 
chronically activate microglia for inflammatory responses, and promote the 
development of tau neurofibrillary tangles (Mucke & Selkoe, 2012; Palop & 
Mucke, 2010; Selkoe, 2002).  
 
The presence of intracellular tau neurofibrillary tangles is the second 
characteristic of the disease. Evidence shows that the development of tau 
neurofibrillary tangles may be caused by Aβ production. Several groups have 
shown that Aβ over-expressing mouse models eventually develop tau as the 
disease progress, but tau mouse models do not produce Aβ (Mucke & Selkoe, 
2012; Palop & Mucke, 2010; Selkoe, 2002). Furthermore, Aβ production leads 
to the cleavage of p35 to p25 by calpain. Together with cyclin dependent 
kinase 5 (Cdk5), p25 can hyperphosphorylate tau (Sundaram et al, 2012). 






1.1.2 Etiology of AD 
Familial AD makes up less than 1% of the total AD population. Genetic 
mutations in the APP, Down Syndrome and mutations in presenilins all 
contribute to early-onset AD (<60 years old) (Huang & Mucke, 2012; Palop & 
Mucke, 2010).  
 
The vast majority of AD patients are sporadic cases. The inheritance of the 
ApoE4 is the principal genetic risk factor for late onset AD (>60 years old) 
(Vance, 2012). Inheriting one copy of the ApoE4 increases the risk of 
developing AD by one three to four times more likely to develop AD, while 
inheriting two copies of the ApoE4 increases this risk by up to twelve times 
(Bales et al, 2009; Holtzman et al, 2012; Huang & Mucke, 2012; Mahley & 
Rall, 2000; Mahley et al, 2006; Palop & Mucke, 2010; Rebeck et al, 2002; 
Youmans et al, 2012). Furthermore, ApoE4 exerts its detrimental effects on 
memory at an earlier age (Mahley & Rall, 2000; Mahley et al, 2006; Trommer 
et al, 2004). In light of this, understanding the role in which ApoE4 play in 
learning and memory, and the possible mechanism through which it affects 
cognition is crucial.  
 
Apart from inheriting genetic risk factors, other risk factors for dementia 
include stroke, traumatic brain injury, vascular diseases as well as age. In 
addition, AD has also been linked to epigenetic mechanisms such as abnormal 




1.1.3 AD and memory loss 
The hippocampus of the brain is the site of memory consolidation and storage, 
and a site of brain atrophy during the development of AD (Brettschneider et al, 
2015; Thompson et al, 2003). During the course of AD development, Aβ is 
accumulated in the hippocampus and in the cerebral cortex, and at late stage, 
Aβ plaques are detected in the subcortical regions of the brain (Brettschneider 
et al, 2015; Serrano-Pozo et al, 2011). While it is still unknown why the 
hippocampus is vulnerable to Aβ attack, it is certain that understanding the 
mechanism underlying memory decay in the hippocampus is important for 
early intervention and better clinical outcome.  
 
Memory decline in AD is usually progressive, unlike vascular dementia 
patients, where memory decline is fast and stepwise. The earliest symptoms are 
often subtle, intermittent episodes of memory lapses. Dennis Selkoe has coined 
AD as a “synaptic failure”. Indeed, synaptophysin, a presynaptic marker 
required for neurotransmitter vesicle fusion was markedly reduced in MCI 
patients (Selkoe, 2002; Serrano-Pozo et al, 2011; Thompson et al, 2003). This 
meant that the disruption of neuronal networks start even without gross Aβ 
being present.  
 
The role of Aβ in memory decline is undisputed. At cellular levels, application 
of Aβ led to impairment of LTP (Alkadhi & Tran, 2014; Criscuolo et al, 2015; 
Hu et al, 2014; Ivanov et al, 2015; Pour et al, 2015; Tu et al, 2014; Varga et al, 
2014; Wang et al, 2015). Interestingly, Aβ can also increase spontaneous 
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action potential firing, leading to epileptic seizures (Palop & Mucke, 2010). 
According to some studies, Aβ can burrow through the cell membrane to form 
calcium permeable pores, leading to aberrant calcium influx and uncontrolled 
release of neurotransmitters (Demuro et al, 2011; Pourbadie et al, 2015). Aβ is 
also known to cause AMPA current downscaling (Chang et al, 2006). The 
increase in AMPA receptors at the postsynaptic membrane is a marker of LTP 
(Malinow, 2003b; Malinow & Malenka, 2002; Man et al, 2003). The loss of 
functional AMPA receptors at the postsynaptic membrane reduces synaptic 
plasticity and response to future stimuli. As AMPA activation leads to NMDA 
activation and consequently transcription of proteins downstream of CREB, 
Aβ induced AMPA removal prevents memory engram formation (Kullmann & 
Lamsa, 2007; Malinow, 2003b; Malinow & Malenka, 2002). When taken to a 
systemic level, AD mouse models have demonstrated significant impairment in 
learning and memory in a wide variety of behavioral experiments (Baeta-
Corral & Gimenez-Llort, 2015; Cho et al, 2015; Huang et al, 2015; Stevens & 
Brown, 2014; Webster et al, 2014; Wu et al, 2015).  
 
Despite a vast array of data supporting the view that Aβ leads to memory 
impairment, we do not know how this impairment is started, and what could be 
done to impede it. This is a huge gap of knowledge that needs to be answered 
in order for effective treatments that delay, or even prevent memory decline in 






1.2 Apolipoprotein E (ApoE) 
 
1.2.1 ApoE Biology 
Apolipoproteins are proteins that function as lipid carriers. In the brain, the 
ApoE is the major apolipoprotein present, and it can be secreted in situ by both 
glia and neurons (Mahley & Rall, 2000; Mahley et al, 2006). The human ApoE 
is a 34kDa protein containing a N-terminus receptor binding domain, and a C-
terminus lipid binding domain (Mahley et al, 2006). As the name suggests, the 
main functions of the ApoE is to re-distribute lipids among cells, hence its 
physiological function is important for the maintenance and repair of the 
cellular membranes of neurons and glia. In response to cellular injury, more 
ApoE are secreted by glia and neurons to transport cholesterol to the site of 
injury for membrane repair (Mahley & Rall, 2000; Mahley et al, 2006). Despite 
its classical role, the C-terminus of the ApoE can also bind other proteins, such 
as Aβ, and it contains a mitochondrial translocation signal (Bien-Ly et al, 
2011; Mahley et al, 2006). Therefore, ApoE expression directly affects Aβ and 
mitochondrial biology. 
 
1.2.2 ApoE isoforms 
Human and mouse ApoE share <50% homology. Human ApoE exists naturally 
in three isoforms, namely the ApoE2 (cys112, cys158), ApoE3 (cys112, 
arg158) and ApoE4 (arg112, arg158), and they differ from each other by 
having either a cysteine or an arginine residue at position 112 and position 158. 
In ApoE4, the presence of arginine at position 112 leads to the displacement of 
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arginine 61, which forms a salt bridge with glutamine 255. This renders the 
ApoE4 to exist in a “molten globule” structure, where the protein does not 
exist in a fully folded or fully unfolded form (Bales et al, 2009; Mahley & Rall, 
2000; Mahley et al, 2006). Some have shown that this “molten globule” 
structure resulted in protein structural instability. ApoE4 was found to denature 
at much lower concentrations of guanidine hydrochloride and urea as 
compared to ApoE3 and ApoE2. The ApoE4 was also shown to be degraded 
more easily by chymotrypsin as compared to ApoE3 and ApoE2 (Mahley et al, 
2006).  
 
Current literature suggests that the less stable structure of ApoE4 was 
responsible for the isoform-dependent differences in cellular pathology. ApoE4 
was implicated with increased Aβ production, cytoskeletal disruption, 
lysosomal leakage and mitochondrial disruption in the brain (Bales et al, 2009; 
Bien-Ly et al, 2011; Bien-Ly et al, 2012; Cramer et al, 2012; Jordan et al, 
1998; Mahley & Rall, 2000; Mahley et al, 2006; Youmans et al, 2012). When 
the “molten globule” structure of ApoE4 was altered either by replacing the 
arginine 61 residue with threonine or by using small structural correctors that 
break the salt bridge, ApoE4 functions similarly to ApoE3 (Mahley & Huang, 
2012).  
 
1.2.3 ApoE and AD 
Human ApoE3 is the most common form of ApoE, and is expressed in about 
80% of the population. ApoE4 and ApoE2 are expressed in ~14% and >7% of 
the population respectively (Mahley & Rall, 2000). However, ApoE4 is the 
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strongest genetic risk factor for AD. ApoE4 carriers account for more than 
50% of all sporadic patients, and inheriting the ApoE4 predisposes one to 
develop AD in a gene-dose dependent manner. ApoE4 also accelerates onset of 
AD (Bales et al, 2009; Bien-Ly et al, 2012; Cramer et al, 2012; Jordan et al, 
1998; LaDu et al, 2000; Li et al, 2012; Mahley & Rall, 2000; Mahley et al, 
2006; Trommer et al, 2005; Youmans et al, 2012). Although the correlation 
between ApoE4 and AD is extensively studied, its mode of action is still 
unknown. It is of extreme interest to understand why the expression of ApoE4 
leads to memory impairment at an earlier age.  
 
The expression of ApoE4 alone is known to affect learning and memory. ApoE 
knock-in mice showed an ApoE isoform dependent difference in learning and 
memory (Johnson et al, 2014; Leung et al, 2012; Pankiewicz et al, 2014; 
Reverte et al, 2013; Rodriguez et al, 2013; Salomon-Zimri et al, 2014; Sultana 
et al, 2013; Villasana et al, 2013; Yang et al, 2013; Yin et al, 2014). While this 
may highlight that ApoE4 alone leads to learning and memory deficits, the 
cause behind it is still unknown. Furthermore, to understand the role of ApoE4 
in early memory decline and finally AD, both the expression of ApoE4 and Aβ 
should be studied, and under physiological conditions.  
 
The current understanding of the role of ApoE4 in AD is that ApoE4 
expression leads to greater plaque formation. This could be the result of either 
accelerated Aβ aggregation or reduced Aβ clearance. In both mice models and 
in vitro systems, ApoE4 provide support for Aβ oligomers to coalesce together 
to form β sheets. Others have also shown an ApoE isoform dependent 
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difference in Aβ clearance. ApoE4 was the least efficient in clearing Aβ via 
the BBB while ApoE2 was the most efficient (Beffert et al, 1998; Garai et al, 

























1.3 Insulin signaling 
 
1.3.1 The insulin signaling pathway 
The insulin receptor (IR) is a heterotetrameric subunit made up of an 
extracellular α subunit, and an intracellular β subunit. Upon binding of insulin 
to the α subunit insulin receptor, the insulin receptor undergoes dimerization 
and tyrosine autophosphorylation. This results in further autophosphorylation 
of the phosphotyrosine binding sites on the intracellular β subunit, which 
serves as docking sites for downstream adaptor proteins to bind to (Gual et al, 
2005; Hemmings & Restuccia, 2012; Manning & Cantley, 2007; Myers et al, 
1994).  
 
The first downstream molecule of the IR is the insulin receptor substrate (IRS-
1). IRS-1 is an important downstream adaptor protein, which contains a 
pleckstrin homology (PH) domain at the N-terminus and an Src homology 2 
(SH2) binding domain at the C-terminus (Myers et al, 1994). IRS-1 is crucial 
for the amplification of the downstream insulin signaling pathway as most 
effector proteins contain the SH2 binding domain and cannot bind directly to 
the IR. As such, IRS-1 serves as an adaptor protein by binding to the IR via its 
PH domain. SH2 containing effector proteins can bind to the IRS-1 at the SH2 
binding region and to specific phosphorylated residues, which increases 
specificity of the downstream effector binding. These effector proteins include 
Grb2 (involved in Ras regulation), SH-PTP2 (a tyrosine phosphatase involved 
in the negative feedback loop), and p85α (the regulatory subunit of PI3K) 
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(Hemmings & Restuccia, 2012; Le Marchand-Brustel et al, 1995; Manning & 
Cantley, 2007; Myers et al, 1994).  
 
PI3K binds to the IRS-1 at tyrosine 908 (Y908) in mice. The human equivalent 
of this site is Y912. Activation of PI3K leads to the conversion of PIP2 to 
PIP3. PIP3 is required for membrane tethering of downstream proteins, such as 
Akt. Akt binding to PIP3 at the plasma membrane allows it to be 
phosphorylated at two sites (Hemmings & Restuccia, 2012; Manning & 
Cantley, 2007; Myers et al, 1994; Ong et al, 2014).  
 
Akt is phosphorylated at threonine 308 (T308) by PDK-1 and at serine 473 
(S473) by mTORC2. The full activation of Akt requires phosphorylation at 
both sites. Phosphorylation of Akt at S473 alone only does not activate Akt, 
and phosphorylation at T308 alone leads to only partial activation. Activated 
Akt is then free to translocate from the cell membrane to other components of 
the cell to amplify the signaling pathway. Some of the downstream effects 
include the inhibition of caspases and promoting CREB phosphorylation. 
Therefore, the PI3K-Akt pathway suppresses cell death and is pro-survival 
(Gual et al, 2005; Hemmings & Restuccia, 2012; Manning & Cantley, 2007). 
 
1.3.2 Insulin in the brain 
The physiological concentration of insulin in the brain is 1-2nM (Talbot et al, 
2012). Very little insulin is produced in the central nervous system and most 
enter the brain via active transport across the BBB. While the exact mechanism 
is still currently unknown, the proposed mechanism involves LRP2 mediated 
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transcytosis of IRs expressed on the epithelium of the BBB (Fernandez & 
Torres-Aleman, 2012). Once in the brain, insulin asserts its effects as a 
neuromodulator, modulating physiological functions such as neuronal survival, 
and in the interest of this project, learning and memory (Fernandez & Torres-
Aleman, 2012; Freychet, 2000; Zhao & Alkon, 2001; Zhao et al, 2004).  
 
The highest concentration of insulin receptors is found in the olfactory bulb 
and they are also concentrated in the hippocampus, cerebral cortex and choroid 
plexus of the brain (Fernandez & Torres-Aleman, 2012; Zhao & Alkon, 2001; 
Zhao et al, 2004). Although the downstream signaling pathway of insulin-like 
growth factor 1 (IGF-1) share common similarities to the insulin signaling 
pathway, the anatomical location of insulin receptors and IGF-1 receptors have 
distinct differences. Unlike the insulin receptors, IGF-1 receptors are not found 
in the hippocampus of the brain and are found in the thalamus (Fernandez & 
Torres-Aleman, 2012). Hence, insulin receptor activation, and not IGF-1 
receptor activation is suggested to be involved in learning and memory 
 
1.3.3 Insulin and learning and memory 
Apart from the fact that insulin receptors are concentrated in the hippocampus, 
several in vivo and in vitro studies provide evidence that downstream insulin 
receptor signaling is crucial for learning and memory.  
 
In rat models, insulin receptor β subunit haploinsufficiency led to deficiencies 
in learning and memory. In the hippocampus slices of these mice, high 
frequency stimulation (HFS) failed to sustain long-term potentiation (LTP). 
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These mice also performed poorly in novel objection recognition tasks (Nistico 
et al, 2012). In a xenopus in vitro model, the expression of a dominant negative 
insulin receptor, which prevented sufficient phosphorylation and activation of 
downstream signaling, led to reduced synaptic density and reduced experience-
dependent dendritic arborization and plasticity (Wang et al, 2003). Taken 
together, these results suggest that a functional insulin signaling is required for 
maintenance of LTP and subsequent learning and memory, although its exact 
mechanism is still unknown. 
 
1.3.4 Insulin and AD 
Interestingly, the AD brain has been described to be at an insulin resistant state 
(Craft & Watson, 2004; Hoyer, 2002). Not only were insulin receptors 
markedly and globally reduced in an AD brain, the response to physiological 
concentrations of insulin were also deficient in the hippocampus formation of 
AD patients (Cole & Frautschy, 2007; Correia et al, 2011; Craft & Watson, 
2004; de la Monte, 2009; Frolich et al, 1998; Talbot et al, 2012). Although 
insulin application led to phosphorylation of the insulin receptor in the 
hippocampus of AD samples, the ensuing downstream activation and 
amplification of the insulin signaling cascade was clearly impaired (Talbot et 
al, 2012). This meant that insulin could not potentiate the downstream 
mechanism.  
 
The implication of insulin signaling dysfunction in AD led to more research 
being poured into trying to increase availability of central levels of insulin. In 
these experiments intranasal insulin was administered to AD patients, and their 
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performance in delayed-recall memory tasks were observed. When comparing 
across the whole cohort, insulin supply improved memory performance. 
However, when stratified into ApoE genotypes, ApoE4 carriers did not benefit 
from this treatment (Craft et al, 2003; Craft & Watson, 2004; Freiherr et al, 
2013). This observation hinted that insulin resistance in the presence of Aβ was 
ApoE isoform dependent, and this affected the memory performance outcome. 
While it is apparent that insulin dysfunction is an observable phenomenon at 
end-stage of AD, it remains unknown if insulin signaling impairment is a 
downstream effect of AD pathology or whether it is a cause of disease 
progression. 
 
As insulin sensitivity contributes to learning and memory, and it is also 
implicated in AD, many groups have attempted to understand the underlying 
mechanism. It was discovered that insulin and Aβ shared common recognition 
motif [RGFFYTPKT], and this motif was required for insulin to bind to the 
insulin receptor (Verdier et al, 2004). Consequently, Aβ was shown to compete 
with insulin for binding to the insulin receptor, thereby blocking downstream 
signaling. It was hypothesized that in AD, more Aβ accumulated would out 
compete insulin for receptor binding (Xie et al, 2002; Zhao et al, 2008). In 
hippocampal slices of wild type (WT) mice, incubation of the slices with Aβ 
disrupted response to insulin and prevented LTP under HFS conditions 
(Townsend et al, 2007). This observation was reversed when the slices were 
first treated with insulin before Aβ incubation. As a proof of concept, when a 
pharmacological antagonist of the insulin receptor (AG1024) was added 
together with these insulin pre-treated slices, LTP could not be stimulated. 
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Furthermore, an insulin-sensitizing drug prevented Aβ induced insulin 
signaling impairment and improved animal performance in memory tasks. In 
sum, these in vitro results provide evidence of an interplay between insulin 
sensitivity and Aβ induced memory impairment.  
 
However, these experimental models are not ideal. Firstly, the experiments 
were not conducted in the presence of the human ApoE, which makes it 
difficult for these results to be translated into a clinical setting. Secondly, it 
remains to be elucidated when insulin resistance begins in the process of 
disease progression, and if it contributes to the worsening of memory, or is a 
















1.4 Objective of Study 
In this study, we are keen to understand how the ApoE4 isoform lead to earlier 
onset of memory decline in the presence of Aβ accumulation. We hypothesize 
that there is an ApoE isoform dependent effect on neuronal insulin signaling in 
the hippocampus which we shall investigate using biochemical, behavioral and 
electrophysiological means.  
 
1.5 Hypothesis and Specific Aims   
 We hypothesize that the co-expression of Apo4 and Aβ42 confers insulin 
resistance and attenuates learning and memory. The specific aims of this study 
are: 
1. To show that the co-expression of ApoE4 and Aβ42 leads to attenuation 
of learning and memory at an earlier time point.    
2. To show that the co-expression of ApoE4 and Aβ42 leads to insulin 












MATERIALS AND METHODS 
 
2.1 Generation of Transgenic Mouse Models 
Experiments involving the use of animals and primary hippocampal neuron 
cultures were carried out in accordance with the approved protocol 13-4468 
and BR 13-4458, reviewed by the Institutional Animal Care and Use 
Committees (IACUC) at the National University of Singapore(Yong et al, 
2014).  
 
The E3XAPP and E4XAPP mice were generated by crossing the human 
ApoE3 and ApoE4 targeted replacement mice (Sullivan et al, 1997), with the 
APP J20 transgenic mice(Mucke et al, 2000). The APP J20 mice carried a 
mutant human APP gene bearing the Swedish (K670N/M671L) and Indiana 
(V717F) mutations. All mice used in the study were bred and housed 
conventionally, under ambient conditions (12hrs dark, 12 hrs light). They were 
kept on 2018 Teklad Global 18% Protein Rodent Diet (Harland Laboratories). 
All experiments were performed on female WT, APP, E3XAPP and E4XAPP 
mice at 26, 52 and 78 weeks of age. 
 
2.2 Human Samples 
The human post-mortem frontal cortex samples were a kind gift from Prof 




2.3 Real-Time PCR (qPCR) of ApoE 
The whole left hemisphere of the mouse brain was homogenized in Trizol (Life 
Technologies) and RNA was extracted using RNeasy Mini Kit (Qiagen). RNA 
was reverse transcribed and 10ng of cDNA was used for qPCR using TaqMan 
primers for both mouse and human ApoE (Life Technologies).  
 
2.4 Amyloid Beta ELISA 
The whole left hemisphere of the mouse brain was first lysed as previously 
described (Ong et al, 2014). Next, the whole brain lysates were diluted 500-
fold in ice-cold 5M guanidine hydrochloride, pH 8, and incubated at room 
temperature with vigorous shaking at 450 rpm for 3 hours. The samples were 
then diluted 100-fold in EIA buffer, provided by the kit and quantification of 
Aβ42/40 ratios were performed according to manufacturer’s instructions using 
the Human Amyloidβ (1-40) (N) Assay Kit and the Human Amyloidβ (1-42) 
(N) Assay Kit (Immuno-Biological Laboratories Co.). 
 
2.5 Immunohistochemistry (IHC) 
Sagittal sections of perfused brains were first treated with 5M guanidine 
hydrochloride, pH 8, for 30min and permeabilized with 0.1% Triton X for 
30min. The sections were blocked with 10% fetal bovine serum (FBS) for one 
hour and incubated with 6E10 antibody (Covance, Cat#SIG-39300) overnight 
at 4oC. Next, the sections were washed and stained with secondary antibody for 
one hour at room temperature and nuclei were stained with DAPI. The sections 
were visualized using an Olympus fluorescence microscope and images were 
captured at 10X.  
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2.6 Immunoblotting 
Mouse and human brain homogenates were prepared and quantified as descried 
in our earlier study (Ong et al, 2014; Yong et al, 2014). The brain lysates were 
run using a 10% Tris-glycine polyacrylamide gel or a NuPAGE® Bis-Tris gels 
(Life Technologies), and transferred overnight at 15V, onto a nitrocellulose 
membrane. The membranes were probed with the following primary antibodies 
and exposed to horseradish peroxidase (HRP)-conjugated secondary antibodies.  
 
The primary antibodies used in this study were anti-human ApoE (Calbiochem, 
Cat#178479), anti-human ApoE (Santa Cruz, Cat#SC98573), anti-mouse ApoE 
(Santa Cruz, Cat#SC6384) anti-P-IRS-1 (Y608) (Millipore, Cat#09-432), anti-
IRS-1 (Cell Signal Tech, Cat#2382), anti-IR (Cell Signal Tech, Cat#3020), anti-
P-Akt (S473) (Cell Signal Tech, Cat#4060), anti-P-Akt (T308) (Cell Signal 
Tech, Cat#2965), anti-Akt (Cell Signal Tech, Cat#4691), anti-Actin (Sigma, 
Cat#A2066), and anti-Aβ (1-17) (6E10) (Covance, Cat#SIG-39300).  
 
Densitometry analysis of the bands was performed as described (Ong et al, 2014; 
Yong et al, 2014), using NIH ImageJ software and by measuring the optical 
densities of the targeted protein bands. The optical densities of the actin bands 
were measured to ensure equal loading of the sample. For quantifying 
phosphorylated proteins, the optical densities of the phosphorylated protein 
bands were measured relative to the targeted total protein level from the same 




2.7 Hippocampal Slice preparation and treatment 
Hippocampal slices from the right hemisphere were extracted and sliced as 
described elsewhere (Sajikumar et al, 2007). The slices were allowed to 
recover in an artificial cerebrospinal fluid (aCSF) bath for 2 hours. The aCSF 
comprised of a modified Krebs-Ringer solution containing (in mM): 124 NaCl, 
4.9 KCl, 1.2 KH2PO4, 2 MgSO4, 2 CaCl2, 24.6 NaHCO3, and 10 D-glucose. 
The pH of ACSF was between 7.3-7.4 when bubbled with 95% oxygen and 5% 
carbon dioxide (carbogen) (Navakkode et al, 2005). For insulin treated 
samples, the slices were acutely treated with 1μM of insulin (Sigma, 
Cat#I9278) after recovery for 30min and collected. The slices were 
immediately snap frozen in liquid nitrogen and stored for further use.  
 
2.8 Preparation of Aβ42 peptides  
Lyophilized Aβ42 and scrambled Aβ42 peptides were purchased from First Base 
and prepared as described elsewhere (Shaked et al, 2006). Briefly, Aβ42 
peptides were weighed out and dissolved in DMSO to make a fresh 500μM 
stock. Concentrations to be used in experiments were diluted from the stock 
and used immediately.  
 
2.9 Immunoprecipitation 
Brain lysates were pre-cleared for 1h at room temperature before incubating with 
anti-human ApoE (Santa Cruz, Cat#SC98573) overnight on a rotating rotor at 
4oC. Pierce Protein A/G Plus Agarose beads (Research Instruments Co. Ltd.) 
were added and the lysates were rotated on a rotating rotor for 4h at room 
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temperature. Subsequently, the beads and lysates were washed 5 times with PBS 
and prepared for immunoblot analysis as described above.  
 
2.10 Sandwich ELISA 
Brain lysates were incubated with varying concentrations of Aβ42 overnight on a 
rotating rotor at 4oC. To capture ApoE, Nunc-Immuno™ MicroWell™ 96 well 
solid plates (Sigma Aldrich, Singapore) were coated with anti-human ApoE 
(Santa Cruz, Cat#SC98573) overnight, and blocked with 10% FCS the following 
day. The incubated brain samples were loaded onto the plates and incubated 
overnight. The following day, the unbound brain samples were removed and the 
plates were then washed. Next, either anti-IR (Cell Signal Tech, Cat#3020), or 
anti-Aβ (1-17) (6E10) (Covance, Cat#SIG-39300) were added and incubated for 
1h. The plates were washed again before adding in mouse horseradish peroxidase 
(HRP)-conjugated secondary antibodies. After 1 hour, 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) solution was added and 
incubated for 20 minutes. The absorbance from the wells was then read at 
absorbance of 410nm. 
 
2.11 Primary Hippocampal Neuron Culture 
Hippocampal neurons were obtained from dissection of P0 pups of either 
ApoE3 (E3) or ApoE4 (E4) mice as previously described using the Papain 
Dissociation System (Worthington, Cat#LK003150) (Sundaram et al, 2012). 
The hippocampus was dissected and titurated 10 times in papain solution and 
incubated at 37oC for 40 minutes. Next, the hippocampi were  spun at 1000rpm, 
4oC for 10min. The supernatant was removed and the pellet was added to the 
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STOP solution (DNase, papain inhibitor and Earles’s Balanced Salt Solution 
(EBSS)). The hippocampi were titurated and left in room temperature for 10 
minutes. The mixture was layered on top of the 10/10 solution (Bovine Serum 
Albumin (BSA) and trypsin inhibitor in EBSS) and then spun at 1000rpm, 4oC 
for 10 minutes. Hippocampal cultures were plated in 6 well plates for 
immunoblotting or on 12mm coverslips that were previously coated with poly-
L-Lysine (Sigma Aldrich). The hippocampal neurons were maintained in 
Neurobasal media (Life Technologies) supplemented with B27, L-glutamine 
and Penicillin Streptomycin (Life Technologies). Ara-C (Sigma Aldrich) was 
added to the culture after 3 days in vitro (DIV). The neurobasal media 
supplementing the neurons were half-changed once every 3 days. The neurons 
were used for experiments when they are at least DIV 10.  
 
2.12 Insulin starvation and treatment of hippocampal neurons 
 
ApoE3 or ApoE4 hippocampal neurons were incubated with either 500nM of 
Aβ42 or scrambled Aβ42 24h prior to starvation. On the day of the experiment, 
the Neurobasal media (Life Technologies) was removed from the wells and the 
neurons were starved in EBSS (Sigma Aldrich) for 2 hours. After starvation, 
2nM of insulin (Sigma Aldrich) was added into the respective wells and 
incubated for 30 minutes. Following the acute insulin treatment, the neurons 





2.13 Radial Maze 
Mice were put through an eight-arm radial maze following a standard protocol. 
The mice used in the Radial Maze were followed longitudinally from 26 to 78 
weeks.  
 
Mice were first put through two days of habituation trial, where they were 
allowed to roam around the maze for 10min. Novel food (Fruit Loops) were 
scattered throughout the maze on the first day. On the second day of habituation, 
the novel food was restricted to the concave food bowls. Before each day of the 
acquisition trials, mice were starved the night before, with water ad libitum.   
 
After habituation, mice were put through a total of 16 acquisition trials, which 
took place over a span of four days. During the acquisition trials, 4 arms were 
baited with food (a small piece of a fruit loop, and placed in the concave food 
plate), and the other 4 arms were not baited. Throughout the entire project, the 
baited and non-baited arms remained the same. The mice were given 5min for 
each trial to locate the food. After each trial, the maze was cleaned thoroughly 
with ethanol, but uneaten food was left intact and eaten food was not replaced.  
 
After the 16th trial, mice were rested for 96h and subjected to the short-term 
memory probe trial. Mice were given only one attempt during the short-term 
memory probe trial for 5min. After the short-term memory probe trial, mice were 
rested for one week before being put through the long-term memory probe trial. 
The long-term memory probe-trial was similar to the short-term memory probe 
trial, where mice were only given one attempt for 5min.  
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During all the trials, the number of entries into a non-baited arm was noted as a 
memory error. Mice were considered to have entered an arm if all four limbs 
were inside the arm.  
 
2.14 Electrophysiology 
Whole-cell patch clamp recordings were made on hippocampal neurons that were 
between DIV11-12. Each neuron was recorded for at least 20min and no 
electronic compensation was given. The recorded neurons were continuously 
perfused with the extracellular mEPSC solution using a multi-barrel perfusion 
system. The extracellular mEPSC was modified from established groups (Lu et 
al, 2001) and it contained (in mM), NaCl, 140; CaCl2, 4; KCl, 5; HEPES, 25; 
glycine, 0.01; TTX, 0.0005; Strychnine, 0.001; bicuculline methiodide, 0.02; pH 
7.2-7.5, osmolarity 320-330 mosmol-1.  The intracellular solution contained (in 
mM) CsCl2, 140; EGTA, 2.5; MgCl2, 2; HEPES, 10; TEA, 2; Mg2ATP, 4, pH 7.2-
7.4, osmolarity 290-300 mosmol-1. Other solutions such as insulin, MK801, and 
DNQX were added on top of the mEPSC solution when required and applied 
from another barrel.  
 
2.15 Surface staining of AMPA receptors 
DIV11-12 hippocampal neurons plated on coverslips were stained for surface 
AMPA receptors. Neurons were incubated with either 500nM of Aβ42 or 
scrambled Aβ42 24h prior to starvation. On the day of experiment, existing 
GluR1 receptors were first labeled using anti-GluR1 (Cell Signaling, 
Cat#13185), which recognizes an extracellular epitope. After one hour, the 
antibody was washed away and labeled with Alexa Fluor 488 (Life 
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Technologies). The neurons were then serum starved in EBSS for 2h and acutely 
treated with insulin for 30min. The cells were washed and fixed with 4% 
Formaldehyde and blocked with 10% FCS. Excess, unlabeled secondary 
antibody was blocked with anti-Rabbit IgG. Next, the neurons were labeled with 
anti-GluR1 (Cell Signaling, Cat#13185) under non-permeabilizing conditions 
and labeled with Alexa Fluor 594 (Life Technologies) to stain newly inserted 
GluR1(Carrodus et al, 2014). Coverslips were mounted onto a microscope slide 
and fluorescent images were captured using a Zeiss LSM-510 laser-scanning 
confocal microscope at 63X. 
  
Statistical analysis 
Statistical significance were calculated using two-tailed Student’s T-test, as 


















3.1 Aβ content in the ageing ApoEXAPP mice 
 
3.1.1 Human ApoE was the dominant ApoE expressed in the 
transgenic mice brains 
 
To examine the connection between ApoE isoforms and brain insulin signaling 
in AD, we crossed the human ApoE-targeted replacement mice with mice 
carrying the familial-AD mutant human amyloid precursor protein (APP). The 
expression of human ApoE in the ApoE-targeted replacement mice was 
controlled by the mouse endogenous murine regulatory elements, which 
allowed human ApoE to be expressed in a physiologically relevant way in the 
brain (Knouff et al, 1999; Sullivan et al, 1997). The mutant APP mice carried 
the Swedish (K670N/M671L) and the Indiana (V717F) mutations 
(APPSwdInd), under the control of the PDGF promoter (Games et al, 1995; 
Mucke et al, 2000; Rockenstein et al, 1995). This replicated the physiological 
expression of APP in the brain, where it was naturally found in neurons. In this 
study, we examined both ApoE3 and ApoE4. The ApoE3 was expressed in the 
majority of the population and together with the ApoE4, they occurred in 
~94% of most populations and were represented in >99% of sporadic AD 
(Holtzman et al, 2012; Mahley & Rall, 2000). In this project, wild type (WT) 







Figure 1. The human ApoE was the dominant ApoE expressed in the E3XAPP and E4XAPP 
mice brains. (A) Real-time PCR analysis confirmed that the levels of mouse ApoE mRNA in 
E3XAPP mice and E4XAPP mice were significantly lower than in APP mice (** p<0.01). (B) 
Immunoblot analyses confirmed that the human ApoE was the dominant ApoE expressed in 













To ensure that human ApoE was the dominant ApoE expressed in our 
transgenic mice, we performed real-time PCR to compare mouse ApoE mRNA 
levels among the APP, ApoE3XAPP (E3XAPP) and ApoE4XAPP (E4XAPP). 
In Figure 1A, real-time PCR analysis confirmed that mouse ApoE mRNA was 
significantly lower in ApoE3-APP (E3XAPP) and ApoE4-APP (E4XAPP) 
mice brains as compared to APP mice. We then examined ApoE expression in 
the four mouse lines using an antibody specific for human ApoE.  No 
detectable human ApoE expression was found in the young and old WT and 
APP mice as these mice expressed only mouse ApoE. Human ApoE expression 
was detected only in E3XAPP and E4XAPP mice (Figure 1B). 
 
 
3.1.2 Aβ deposition in E4XAPP were significantly higher than 
APP and E3XAPP mice  
 
To characterize the effects of ApoE isoforms on Aβ42 accumulation in the 
brain, we quantified Aβ42 and Aβ40 levels in whole brain lysates of APP, 
E3XAPP and E4XAPP mice at 26, 52 and 78 weeks. These time points were 
selected to represent young (26 weeks), middle (52 weeks), and old (78 weeks) 
age mice. WT was removed from this experiment, as these mice did not 
express APP. The results were expressed as a ratio of Aβ42/40 as Aβ42 was the 








Figure 2. Aβ42/40 ratios in E4XAPP are significantly higher than APP and E3XAPP mice from 
52 weeks. Aβ42/40 ratios were quantified using whole brain lysates at 26, 52 and 78 week old 
APP, E3XAPP and E4XAPP mice. Aβ42/40 ratios in E4XAPP were significantly higher than 
APP (* p<0.05, ** p<0.01) and E3XAPP (## p<0.01) mice at 52 week and 78 week old. 


















At 26 weeks, there was no significant difference in the Aβ42/40 ratios between 
APP, E3XAPP and E4XAPP mice (Figure 2). However, at 52 weeks, Aβ42/40 
ratios in E4XAPP mice became significantly higher than APP and E3XAPP 
mice. The Aβ42/40 in E4XAPP mice was 41.9% higher as compared to APP 
mice, and 51.4% higher compared to E3XAPP mice. At 78 weeks, although 
Aβ42/40 ratios in all three lines increased, the increase was the greatest in 
E4XAPP mice. As compared to APP mice, the Aβ42/40 ratio in E4XAPP mice 
was 34.7% higher. This Aβ42/40 ratio in E4XAPP mice was 49.5% higher as 
compared to E3XAPP mice.  
 
The hippocampus was the site of the brain where early Aβ peptide deposition 
occurred in AD (Serrano-Pozo et al, 2011). Naturally, Aβ42 induced deficits 
should occur early in the hippocampus at the early stages of the disease. In 
patients, these might give rise to the initial symptoms of seemingly benign 
complaints of forgetfulness (Mucke & Selkoe, 2012; Selkoe, 2002). Continued 
accumulation of Aβ to pathological levels in the hippocampus resulted in death 
of hippocampal neurons, and the impairment of cognitive faculties ensued 
(Palop & Mucke, 2010; Selkoe, 2002). In light of this, we wanted to observe 
the extent of Aβ accumulation occurring in the hippocampus of our mice as 
they aged. We observed plaque load in the brains using immunohistochemistry 
(IHC) staining for Aβ on fixed tissues of WT, APP, E3XAPP and E4XAPP 





















Figure 3. (A-C) Immunohistochemistry staining of WT, APP, E3XAPP and E4XAPP 
hippocampus for amyloid plaques using 6E10 antibody at 26, 52 and 78 weeks. (D) 
Quantification of immunohistochemistry staining. Plaque load in E4XAPP mice were the 
highest among the mice at 52 weeks and 78 weeks when compared to APP (** p<0.01) and 















Our results showed that in the presence of ApoE4, plaque load in the 
hippocampus was significantly higher than compared to APP or E3XAPP 
mice. This difference became apparent at 52 weeks, suggesting that the 
presence of ApoE4 led to faster accumulation of amyloid plaques in the brain. 
These results suggested that changes in Aβ burden were ApoE isoform-
dependent, and this finding was consistent with other ApoE-APP mouse lines 
(Bales et al, 2009; Bien-Ly et al, 2011; Bien-Ly et al, 2012; Rodriguez et al, 



















3.2 ApoE isoform-specific effects on brain insulin signaling  
 
3.2.1 ApoE modulation on basal expression of proteins within 
the insulin signaling pathway in ApoEXAPP mice 
 
Current literature showed that basal expression of proteins within the insulin 
signaling pathway was reduced in AD post-mortem brains (Craft & Watson, 
2004; Frolich et al, 1998; Hoyer, 2002). However, these studies represented the 
manifestation of the disease at its end-stage. A major disadvantage of using 
human samples was that it was impossible to observe the protein expression of 
targets downstream of the insulin receptor, as the disease progressed. Using our 
mouse models, we first needed to correlate ApoE isoform and Aβ co-
expression to changes in protein expression within the insulin signaling 
pathway. We first investigated the non-stimulated expression of these proteins 
in the brains of our mouse models at 26, 52 and 78 weeks. Our main targets 
were phosphorylated IRS-1 Tyr608 (Y608), and Akt serine 473 (S473) and 
threonine 308 (T308). We chose not to probe for phosphorylated insulin 
receptor as previous literature had shown that despite activating the insulin 
receptor by Y1151 phosphorylation, downstream insulin signaling did not 
ensue as IRS-1 Y608 phosphorylation was deficient (Talbot et al, 2012). 
Hence, probing for downstream activation of the insulin receptor such as IRS-1 
Y608 phosphorylation and activated Akt was a more accurate indicator of 
insulin receptor activation. IRS-1 Y608 was the binding site for the p85 subunit 
of PI3K (Gual et al, 2005; Hemmings & Restuccia, 2012; Myers et al, 1994). 
Furthermore, activation of Akt was the indicator of subsequent PI3K activity, 
and amplification of the insulin signaling cascade(Hemmings & Restuccia, 




















Figure 4. Basal levels of protein expression downstream of the insulin receptor were 
reduced in APP and E4XAPP brains at 78 weeks. (A, C, E) Representative immunoblots of 
WT, APP, E3XAPP and E4XAPP at 26, 52 and 78 week old, respectively. Equal loading 
was confirmed by re-probing the same membrane with anti-actin antibody. (B, D, F) 
Quantification of immunoblot analyses with densitometry. Results were expressed as a fold 
change in protein expression as compared to WT. At 78 weeks, protein expression of P-
IRS-1 Y608, IRS-1, P-Akt S473 and P-Akt T308 in APP mice were markedly reduced 
compared to WT (* p<0.05, ** p<0.01) and E3XAPP (§§ p<0.01) brains.  A greater 
reduction in protein expression of P-IRS-1 Y608, IRS-1, P-Akt S473 and P-Akt T308 was 
observed in E4XAPP mice when compared to WT (** p<0.01), and E3XAPP mice (§§ 
p<0.01). ApoE expression was also lower in E4XAPP mice than in E3XAPP mice (§§ 
p<0.01). Only P-IRS-1 Y608 and IRS-1 were significantly lower in E4XAPP mice when 






















At 26 and 52 weeks, there were no differences in the expression and 
phosphorylation of IRS-1 and Akt between WT, APP, E3XAPP and E4XAPP 
mice brains (Figure 4 A-D). In the aged mice brains (78 weeks) however, IRS-
1 expression and phosphorylation at Y608 were lower in APP and E4XAPP 
mouse brain (Figure 4E, F). Phosphorylated IRS-1 Y608 expression in APP 
mouse brain was 19.6% and 9.6% lower than in WT and in E3XAPP mouse 
brain respectively. The expression of phosphorylated IRS-1 Y608 in E4XAPP 
mouse brain was 42.8%, 28.9% and 38.5% lower than in WT, APP and 
E3XAPP mouse brains respectively. Expression of IRS-1 in APP was 40.7% 
and 22.8% lower compared to WT and E3XAPP mouse brains respectively. In 
E4XAPP mouse brains, IRS-1 expression was 64.2%, 39.7% and 62.5% lower 
compared to WT, APP, and E3XAPP mouse brains respectively. While 
phosphorylation of IRS-1 Y608 and IRS-1 expression was lower in E3XAPP 
mouse compared to WT mouse brains, the decrease was not significant.  
 
In contrast, brain Akt expression was comparable between WT, APP, E3XAPP 
and E4XAPP mice (Figure 4E, F). However, Akt phosphorylation at S473 and 
T308 were lower in APP and E4XAPP as compared to WT and E3XAPP. 
Phosphorylated Akt S473 was reduced by 50.5% and 49% in APP brains 
compared to WT and E3XAPP brains respectively. In E4XAPP brains, the 
expression of phosphorylated Akt S473 was 50.1% and 48.6% lower than in 
WT and E3XAPP brains respectively. Similarly, phosphorylated Akt T308 was 
reduced by 32.7% and 38.9% in APP mouse brains compared to WT and 
E3XAPP brains respectively. The expression of phosphorylated Akt T308 in 
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E4XAPP mouse brain was 48.7% and 52.8% lower as compared to WT and 
E3XAPP brains respectively.  
 
At 26 and 52 weeks, there was no detectable change in human ApoE 
expression between E3XAPP and E4XAPP (Figure 4 A-D). However, when 
the mice aged (at 78 weeks), human ApoE expression was reduced by ~50% in 
E4XAPP as compared to E3XAPP mice (Figure 4E, F).  
 
 
3.2.2 ApoE modulation on brain insulin signaling in human 
post-mortem samples 
 
To ensure that our results from the mouse models were clinically relevant and 
in line with existing reports, we performed the same immunoblot analysis on 
the frontal cortex of human brain samples (Figure 5). We compared between 
ApoE3/3 homozygous control cases (3/3 control), ApoE3/3 homozygous AD 
cases (3/3 AD) and ApoE4/4 (4/4 AD) homozygous AD cases. We used ApoE 
homozygous cases, as we did not want heterozygosity in ApoE isoform to 
affect analysis of the data. In addition, when using heterozygous samples, it 
was not possible to decipher which of the two ApoE isoforms was dominant 









Figure 5. Expression of proteins downstream of the insulin receptor, were reduced in human 
AD brains. (A) Immunoblot analyses of homozygous 3/3 control, 3/3 AD and 4/4 AD cases 
showed reduced downstream insulin signaling in all AD cases. Equal loading was confirmed 
by re-probing the same membrane with anti-actin antibody. (B) Quantification of immunoblot 
analyses with densitometry. Results were expressed as a fold change in protein expression as 




When comparing against 3/3 control cases, we observed an 82.2% and 83.8% 
reduction in phosphorylated IRS-1 Y612 expression in 3/3 AD and 4/4 AD 
cases respectively (Figure 5B). IRS-1 Y612 was the human equivalent to Y608 
in mice. Reflective of this observation, we also observed a 79.4% and 86.7% 
reduction in IRS-1 expression in 3/3 AD and 4/4 AD cases. Furthermore, there 
was also a 59.9% and 76.7% reduction in phosphorylated Akt S473 expression 
levels and a 50.9% and 52.5% reduction in phosphorylated Akt T308 
expression levels in 3/3 AD and 4/4 AD cases, respectively. In sum, our results 
confirmed that the insulin signaling pathway was impaired at the end-stage of 

















3.3 ApoE isoform differences in insulin receptor binding  
 
3.3.1 ApoE3 bind more strongly to the IR than ApoE4 
 
Aβ and insulin share a similar common recognition motif [RGFFYTPKT], 
which is the sequence required for insulin to bind to the insulin receptor (IR) 
(Verdier et al, 2004). As such, this had led to many reports showing the 
binding of the Aβ to the IR, resulting in insulin signaling impairment 
(Townsend et al, 2007; Xie et al, 2002; Zhao et al, 2008). In spite of these 
results, we found that these studies were conducted in the absence of human 
ApoE, and the role of human ApoE isoforms in this process was unknown. Aβ 
could also bind to ApoE albeit with different isoform-dependent affinities. The 
current standing in this area of research is that ApoE4 supports and promotes 
oligomerization of Aβ peptides, thereby increasing plaque formation (Beffert 
et al, 1998; Garai et al, 2014). While different groups had shown conflicting 
reports as to which ApoE isoform binds Aβ more, it should be highlighted that 
these studies were either done using transfected cell lines or synthetic ApoE, 
which may not represent ApoE in a physiologically relevant way (Tai et al, 











Figure 6. Binding of ApoE3 to the IR and ApoE4 to Aβ occurs at an early time point. (A) 
Representative immunoblots of bound antigens immunoprecipitated with anti-human ApoE 
antibody in mouse models (n=6). ApoE3 was associated more strongly to the IR than ApoE4 
from 26 weeks. ApoE4 associated more with Aβ from 26 weeks, and this association increased 
as the E4XAPP mice aged to 78 weeks. Equal amounts of antibody incubated with each sample 
are confirmed with probing the membrane for the IgG heavy chain. (B) Representative 
immunoblots of bound antigens immunoprecipitated with anti-human ApoE antibody in human 
frontal cortex samples (n=4 per case). IR was less associated with ApoE in all AD cases. 
Comparing between 3/3 AD and 4/4 AD cases, more Aβ was bound to the 4/4 AD than to 3/3 
AD. Equal amounts of antibody incubated with each sample were confirmed by probing the 
membrane for the IgG heavy chain. (A-B, bottom) Representative immunoblots of lysates 
used in immunoprecipitation. Equal amounts of protein used were confirmed by re-probing the 
same membrane with anti-actin antibody.  
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To determine if ApoE could bind with the insulin receptor, we 
immunoprecipitated human ApoE from 26, 52 and 78 week old brain lysates of 
our E3XAPP and E4XAPP mice and included WT and APP mice as control 
(Figure 6A). At all ages, we detected a stronger ApoE3 binding with IR than 
ApoE4. When Aβ level increased in 78 weeks, ApoE4 bonded Aβ stronger 
than ApoE3. This difference was not due to changes in IR expression, as 
similar IR content was observed in the brain lysates. Next, we performed the 
same immunoprecipitation experiment on the human post-mortem brain 
samples and observed that there was a decreased binding of the ApoE to the IR 
in all AD cases, regardless of ApoE isoform (Figure 6B). In contrast, we 
observed that in the 3/3 control cases, there was a stronger binding of the 
ApoE3 to the IR. However, the AD cases represent the end-stage of the 
disease, hence our data suggests the binding of ApoE to IR at an earlier time 
point could provide resilience to Aβ impairment of the insulin signaling 
pathway, and its subsequent consequences.  
 
 
3.3.2 ApoE3 binding to IR is independent of Aβ42 
concentrations  
 
As E4XAPP mice had greater Aβ accumulation in the brain at 78 weeks, we 
asked if this ApoE-IR association was isoform dependent, and if it was affected 
by increasing Aβ42 concentrations. To investigate this, we set up a sandwich 
ELISA to capture ApoE from our ApoE3 and ApoE4 mice. These ApoE mice 





Figure 7. ApoE3 bound more than ApoE4 to the IR regardless of Aβ42 concentration. To 
measure the amount of ApoE3 and ApoE4 bound to the IR under identical concentrations of 
Aβ42, whole brains lysates from ApoE3 KI and ApoE4 KI mice were incubated with 0, 10, 30, 
150, 500 and 1000nM of Aβ42 for 24h before performing the sandwich ELISA. (A, C) 
Regardless of Aβ42 concentration, ApoE3 bound more to the IR more than ApoE4 did (* 
p<0.05, ** p<0.01). Scrambled Aβ42 was used as a control for Aβ42. (B) At low concentrations 
of Aβ42 (0-30nM), ApoE3 and ApoE4 showed similarity in binding preference for Aβ42. As the 
concentrations of Aβ42 increased, ApoE4 showed greater binding preference to Aβ42 than 













After blocking and washing, the wells were incubated with increasing 
concentrations of synthetic Aβ42. Unbound Aβ42 were then removed and the 
wells were probed with either anti-IR or anti-Aβ. As shown in Figure 7A, the 
level of IR bound to the captured ApoE3 was independent to the added Aβ42 
concentrations. On the other hand, ApoE3 and ApoE4 had similar abilities to 
bind to Aβ42 between 0-30nM. However, ApoE4 associated with more Aβ42 as 
the concentrations increased beyond 30nM (Figure 7B). Incubation with 




















3.4 Co-Expression of ApoE4 and Aβ42 impaired response to 
insulin stimulation 
 
3.4.1 ApoE4 and Aβ42 peptide impaired insulin signaling in 
hippocampal neurons 
 
We wanted to know if ApoE4 expression was sufficient to cause insulin 
signaling impairment, or if the insulin signaling deficit was a result of the co-
















Figure 8. Insulin stimulation in the presence of Aβ42 was impaired in ApoE4 hippocampal 
neurons. (A) Immunoblot analyses of ApoE3 and ApoE4 hippocampal neurons were incubated 
for 24h with either scrambled Aβ42 or Aβ42 and subjected to the insulin (2nM) stimulation for 
30min. Insulin signaling in the presence of Aβ42 was impaired in ApoE4 hippocampal but not 
in ApoE3 hippocampal neurons. (B) Quantification of immunoblot analyses with densitometry. 
Results were expressed as a fold change in protein expression as compared to the non-treated 









Using DIV10 ApoE3 and ApoE4 neurons, physiological concentrations of 
insulin treatment (2nM) led to a nearly 2-fold increase in activated IRS-1 
(Y608) and, and a nearly 3-fold increase in Akt (S473 and T308) 
phosphorylation in both neuronal lines (Figure 8A, B). 500nM Aβ42 or 
scrambled Aβ42 peptides added to ApoE3 and ApoE4 hippocampal neurons had 
no effect on IRS-1 and Akt expression and phosphorylation, similar to non-
treated neurons. The Aβ42 concentration used in our study was comparable to 
other studies used on primary neurons (Zhao et al, 2008). We found an 
impaired response to insulin in the presence of Aβ42 was ApoE isoform 
dependent (Figure 8A, B). When ApoE3 hippocampal neurons were pre-treated 
with Aβ42, acute insulin treatment led to an 86.94% increase in phosphorylated 
IRS-1 Y608 expression (Figure 8B), which was further translated into about 3-
fold increase in phosphorylated Akt S473, and Akt T308 expression (Figure 
8B). When ApoE4 hippocampal neurons were subjected to the same treatment, 
prior incubation of the neurons with Aβ42 resulted in an evident attenuation in 
response to insulin.  
 
Our results show that insulin signaling impairment in the presence of Aβ42 was 
isoform specific, where expression of ApoE4 impeded response to insulin 
stimulation. We also noted that insulin and/or Aβ42 treatment have no effect on 
ApoE level. Similar to Figure 4, there were two ApoE bands, the native 34kDa 
protein and the higher molecular weight sialylated ApoE isoprotein. Sialylated 
ApoE isoproteins associated with neurons in human ApoE transgenic mice and 
in human brain, and they contribute significantly (~60%) to the total neuronal 
ApoE level(Xu et al, 1999). 
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3.4.2 Insulin signaling impairment in the hippocampus of 
E4XAPP mice was an early event 
 
In the clinic, AD patients usually start by having difficulties in recalling recent 
events. Most of the time, these episodes of memory slips would be brushed 
aside as being insignificant or just being forgetful, as patients at the earliest 
stage of AD were mostly neurologically intact (Palop & Mucke, 2010; Selkoe, 
2002). As the loss of memory and subsequent cognitive impairment in AD is 
insidious, more focus is being placed on the earlier stages of the disease 
progression. Synaptophysin, a vesicular protein and surrogate presynaptic 
marker was ~25% reduced in post-mortem samples of patients diagnosed with 
MCI or very mild AD, suggesting that synaptic failure was an early event in 
AD progression (Selkoe, 2002). This also meant that subtle deterioration of 
memory in these individuals started even in the absence of gross amyloid 
pathology (Selkoe, 2002). Interestingly, insulin response in the hippocampus of 
AD post-mortem cases was significantly impaired when compared to control 
cases (Talbot et al, 2012). Till this date, there had been no reports documenting 
insulin response in the hippocampus as the disease progressed. In light of this, 
we asked if insulin response in the hippocampus of the mice would differ as 
















Figure 9. Insulin signaling impairment in the hippocampus of E4XAPP mice occurs at an early 
time point. (A-C) Immunoblots of hippocampal slices from WT, APP, E3XAPP and E4XAPP 
mice were treated with or without 1μM of insulin. The hippocampus of E4XAPP mice was not 
sensitive to insulin stimulation from 26 weeks. APP mice started to show insulin signaling 
deficits at 52 weeks, while WT and E3XAPP mice were sensitive to insulin stimulation from 
26 to 78 weeks. Results were expressed as a fold change in protein expression as compared to 
the non-treated slices within the same mouse line (* p<0.05, ** p<0.01). Error bars represent 












Following dissection, the mouse hippocampal slices were rested for 2 hours 
before being treated with 1μM of insulin for 30 minutes. Our immunoblot 
analyses show that the hippocampal slices of E4XAPP mice were not 
responsive to insulin stimulation at 26 weeks of age, where there was little Aβ 
plaque deposition in the hippocampus (Figure 3A). At 26 weeks of age, 1μM 
of insulin was able to result in a marked increase in phosphorylated Akt S473 
and Akt T308 expression in WT, APP and E3XAPP mice (Figure 9A). At 52 
and 78 weeks, unlike WT and E3XAPP mice, both the APP and E4XAPP mice 
were unresponsive to insulin stimulation (Figure 9 B-C). At 78 weeks, 1μM of 
insulin led to a nearly 3-fold increase in phosphorylated Akt S473 and Akt 
T308 in WT mice. While the response to insulin was reduced in the E3XAPP 
mice at 78 weeks, insulin stimulation still led to ~25% increase in Akt 
phosphorylation. In sum, we demonstrated that in the presence of the ApoE4, 
insulin response in the hippocampus was clearly impaired at a young age, even 
in the absence of amyloid plaques. While ApoE3 was not known to be 
neuroprotective, its expression could have provided some plasticity to buffer 









3.5 Spatial memory impairment in E4XAPP mice was an early 
event 
 
Inheriting the one copy of the ApoE4 allele predisposes one to develop AD 
symptoms at an earlier age (Mahley et al, 2006). With this knowledge and our 
results from Figure 6, we were curious if the co-expression of ApoE4 and APP 
would affect spatial memory performance in our mice as they aged, and if it 
could be associated with insulin sensitivity in the hippocampus. To investigate 
if the mice exhibited spatial memory impairment, we tested each mouse using 
an eight-arm Radial Maze. In this experiment, mice underwent 16 acquisition 
trials, followed by a short-term memory probe trial and a long-term memory 
probe trial. The 16 acquisition trials conducted in the protocol served to allow 
mice to remember where the baited and un-baited arms were. Their 
performances during these 16 trials could also be used to gauge their ability to 
consolidate memories. The short-term memory probe trial and long-term 










Figure 10. Spatial memory impairment was an early event in E4XAPP mice. (A) To assess 
learning and spatial memory, mice were tested using an eight-arm radial maze at 26, 52 and 78 
weeks. Following 16 acquisition trials, mice were tested for short-term and long-term memory 
retention at 96h after the 16th trial and 1 week after the short-term trial. E4XAPP mice showed 
both short-term and long-term memory deficits at as early as 26 weeks when compared to WT 
(** p <0.01), APP (# p<0.05) and E3XAPP (§§ p<0.01). At 52 weeks, both APP and 
E4XAPP mice showed memory deficits when compared to WT (** p <0.01) and E3XAPP (§ 
p<0.05, §§ p<0.01), but E4XAPP mice performed worse than APP mice during the short-term 
and long-term memory trial (# p<0.05, ## p<0.01). At 78 weeks, both APP and E4XAPP 
mice showed learning deficits after the first day of memory acquisition as compared to WT (* 
p<0.05, ** p <0.01) and E3XAPP (§ p<0.05, §§ p<0.01) mice. From the fourth day of 
memory acquisition training onwards, the E4XAPP mice made more spatial memory errors as 
compared to the APP mice (# p<0.05, ## p<0.01). At 78 weeks E3XAPP mice made more 
errors than WT mice only at the long-term memory trial (* p<0.05). Error bars represent 
±SEM (n=7-10). 
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Our radial maze results show that E4XAPP mice performed worse than the 
WT, APP and E3XAPP mice for the short-term and long-term memory trials at 
as early as 26 weeks old (Figure 10A). When compared to the other mice, 
E4XAPP mice made two times more errors at the short-term memory probe 
trial and made nearly three times more mistakes during the long-term memory 
probe trial. Interestingly, this poorer performance in recalled-memory tasks can 
be co-related to unresponsiveness to insulin stimulation in the E4XAPP 
hippocampus. At 52 weeks old, both the APP and E4XAPP mice exhibited 
spatial memory deficits and made more errors when compared to WT and 
E3XAPP mice. However when compared with each other, the E4XAPP mice 
made more spatial memory errors than the APP mice during the short-term and 
long-term memory probe. As the mice progress to 78 weeks old, both the APP 
and E4XAPP mice showed memory acquisition deficits, as well as impaired 
short-term and long-term memory when compared to the WT and E3XAPP 
mice. However, when compared to each other, the E4XAPP mice showed more 
severe memory deficits and made significantly more errors than the APP mice 
from the fourth day onwards. 
 
All things considered, we showed that ApoE4, with just low levels of Aβ42/40 
ratios, was sufficient to attenuate downstream insulin signaling. We also 
demonstrated that under such conditions, E4XAPP mice exhibited deficits in 
both short-term and long-term memory at an early age. Our data suggest that 
this resultant unresponsiveness to insulin could cause the earlier deterioration 
of memory in the E4XAPP mice. 
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3.6 Insulin-induced AMPA insertion was ApoE isoform 
dependent  
 
3.6.1 Insulin sensitivity increases postsynaptic AMPA GluR1 
subunit insertion  
 
The study of synapses in AD was crucial as synapses form the most 
fundamental unit of memory formation (Malinow, 2003a; Selkoe, 2002). Aβ42 
induced synaptic loss initiates neuronal death, which spearheads memory 
erosion (Bien-Ly et al, 2011; Chang et al, 2006; Cole & Frautschy, 2007; 
Gandy, 2005; Selkoe, 2002). Interestingly, it was reported that insulin could 
increase AMPA GluR1 subunit insertion, and increase in AMPA 
postsynaptically was synonymous with an increase in synaptic strength 
(Malinow, 2003b; Malinow & Malenka, 2002; Passafaro et al, 2001). To see if 
we could replicate this observation, we differentially stained the surface for 


































Figure 11. Insulin stimulation promoted insertion of new GluR1 whereas Aβ42 pre-treatment 
impaired basal GluR1 insertion. (A, B) Immunocytochemistry staining of ApoE3 and ApoE4 
hippocampal neurons with anti-GluR1. (C) Quantification of newly inserted GluR1 expression. 
Results were expressed as a fold change against non-treated neurons of the same genotype. 
More GluR1 were inserted in insulin treated neurons as compared to the non-treated group of 
the same genotype (** p<0.01). Pre-treatment of neurons with Aβ42 reduced new GluR1 
expression in both ApoE3 and ApoE4 neurons (** p<0.01). In ApoE3 neurons, stimulation 
with insulin rescued Aβ42 reduction of new GluR1 expression (## p<0.01), and was 
significantly higher than its ApoE4 counterparts (§§ p<0.01). In ApoE4 neurons, Aβ42 
reduction in new GluR1 expression were not rescued with insulin stimulation, and remained 












In Figure 11 A-C, 2nM of insulin resulted in an almost 3-fold increase in 
GluR1 subunit insertion in both ApoE3 and ApoE4 neurons. On the other 
hand, pre-treatment with Aβ42 reduced the number of newly inserted GluR1 
subunits in both genotypes by ~50%. However, when Aβ42 pre-treated ApoE3 
neurons were stimulated with 2nM of insulin, an almost 3-fold increase was 
observed. This increase in GluR1 subunit insertion was not observed when 
Aβ42 pre-treated ApoE4 neurons were treated with insulin. In the presence of 
ApoE4 and Aβ42, insulin treatment was unable to increase new GluR1 
insertion. Taken together, this result confirmed that sensitivity to insulin 
stimulation led to more AMPA receptors being inserted into the membrane. It 
further highlighted that an ApoE-isoform dependent difference in insulin 
sensitivity in the presence of Aβ42 resulted in a difference as to whether AMPA 
GluR1 subunits could be inserted into the postsynaptic membrane.  
 
 
3.6.2 Insulin stimulation increased AMPA mEPSC amplitude in 
glycine-induced LTP 
 
To understand how ApoE isoforms and their co-expression with Aβ42 could 
modulate memory at synaptic level, we turned our focus to study the miniature 
excitatory postsynaptic current (mEPSC) in hippocampal neurons. mEPSC 
could be used to measure the probability of neurotransmitter release by the 
presynaptic neuron or changes to the number of receptors on the postsynaptic 
neuron (Lu et al, 2001; Man et al, 2003). Under such conditions, the release of 
endogenous neurotransmitter from the presynaptic neuron binds to its receptor 
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and results in mini spontaneous depolarization events to occur at the 
postsynaptic neuron (Lu et al, 2001; Man et al, 2003).  
 
 We simulated learning and memory by observing LTP in the neurons. LTP 
was the cellular analogue for learning and memory, and characterized by the 
increase in AMPA receptors, postsynaptically (Kullmann & Lamsa, 2007; 
Malinow, 2003a; Malinow & Malenka, 2002). Here, we tested if insulin 
sensitivity led to LTP by chemically inducing LTP with glycine. Glycine was a 
co-agonist of the NMDA receptor (Lu et al, 2001). The mechanism underlying 
glycine-induced LTP involved the activation of both NMDA receptors and 
PI3K activity (Chan et al, 2011).  In this experiment, we used endogenous 
glutamate released by the presynaptic neurons and patched the postsynaptic 
neuron under gap-free conditions. TTX was added to prevent spontaneous 
action potential firing, glycine receptor antagonist strychnine and GABA 
receptor antagonist bicuculline were also added (Man et al, 2003).  
 
Although glycine is a co-agonist of the NMDA receptor, glycine-induced 
AMPA insertion can take place with or without changes to the NMDA mEPSC 
(Lu et al, 2001; Man et al, 2003). Interestingly, both AMPA and NMDA 
current downscaling were reported in AD mouse models, and insulin 
application can either remove or insert AMPA receptors at the postsynaptic 
membrane (Ahmadian et al, 2004; Lin et al, 2000; Passafaro et al, 2001). At 
high concentrations (μM), insulin led to AMPA receptor endocytosis, whereas 
at concentrations nearer to the physiological concentration (nM), insulin 
treatment resulted in AMPA receptor insertion (Ahmadian et al, 2004; Lin et 
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al, 2000; Passafaro et al, 2001). In this experiment, we used ApoE3 and ApoE4 
hippocampal neurons, and measured the changes in NMDA and AMPA 
















      
     
 
Figure 12. Insulin stimulation led to increase in AMPA mEPSC amplitude in glycine-induced 
LTP. (A) Representative traces of mEPSC recordings of the same neuron taken immediately 
before and after MK801 (5μM) perfusion. In the presence of insulin, AMPA mEPSC 
amplitudes were increased. (B) mEPSC interval and amplitude histograms summarizes results 
from ApoE3 and ApoE4 hippocampal neurons, treated with or without insulin and MK801. 
Insulin application did not increase mEPSC intervals. As compared to non-treated hippocampal 
neurons within the same genotype, perfusion of MK801 reduced NMDA mEPSC amplitude 
(** p<0.01). Insulin stimulation led to an increase in AMPA mEPSC amplitude when 





To investigate which receptor was modulated by insulin action, we added 
MK801, an irreversible NMDA inhibitor to block out the NMDA mEPSC and 
to isolate the AMPA mEPSC. When comparing between non-treated (NT) 
neurons within the same ApoE isoform, addition of MK801 led to a significant 
reduction in the amplitude total mEPSC current (Figure 12A, B). This was an 
expected outcome as this reduction in mEPSC amplitude represented the 
NMDA component of the mEPSC. After insulin treatment, we observed an 
increase in AMPA mEPSC amplitude in both ApoE3 and ApoE4 hippocampal 
neurons. Throughout this experiment, we did not observe changes in mEPSC 
frequency with the addition of insulin. Taken together, it suggested that insulin 




3.6.3 Insulin sensitivity rescued Aβ42 down-regulation of AMPA 
mEPSC amplitude  
 
We were curious how the ApoE isoform-dependent effects on insulin signaling 
in the presence of Aβ42 would manifest itself on AMPA receptor mEPSC 
changes. In this set of experiments, we added DNQX to ensure that we 



























Figure 13. Insulin stimulated increase in AMPA mEPSC amplitude in glycine-induced LTP 
was impaired in ApoE4 hippocampal neurons pre-treated with Aβ42 (500nM). (A-B) 
Representative traces of mEPSC recordings of the same neuron taken immediately before and 
after DNQX (5μM) perfusion. (C) mEPSC interval and amplitude histograms summarizes 
results from ApoE3 and ApoE4 hippocampal neurons. In the presence of Aβ42, intervals 
between each AMPA mEPSC event were markedly increased when compared to non-treated 
neurons of the same genotype (** p<0.01). Application of insulin did not reverse this 
observation. Amplitudes of AMPA mEPSC in insulin treated neurons were higher as compared 
to the non-treated group within the same genotype (* p<0.05). Pre-treatment of neurons with 
Aβ42 reduced AMPA mEPSC amplitude in both ApoE3 and ApoE4 neurons (** p<0.01). In 
ApoE3 neurons, stimulation with insulin rescued Aβ42 induced reduction in AMPA mEPSC 
amplitude (## p<0.01). The rescued AMPA mEPSC amplitude in ApoE3 neurons was 
comparable to that of the non-treated group, and higher than its ApoE4 counterparts (§§ 
p<0.01). The AMPA mEPSC amplitude of ApoE4 neurons pre-treated with Aβ42 were not 
rescued with insulin stimulation, and remained lower than its non-treated group (** p<0.01). 








As shown in Figure 13 A-C, we showed that in both genotype, addition of 
insulin led to an increase in AMPA mEPSC amplitude. On the other hand, 
addition of Aβ42 reduced AMPA mEPSC frequency and amplitude. However, 
when ApoE3 neurons were treated with insulin, insulin stimulation reversed 
Aβ42 induced mEPSC amplitude reduction. This was not observed in ApoE4 
neurons treated in a similar way. While the rescue in AMPA mEPSC amplitude 
was only comparable to that of the non-treated group, it suggested that the 
presence of the ApoE3, unlike the ApoE4, was able to endure the detrimental 
effects of Aβ42 when being responsive to insulin. In addition, we noticed that 
Aβ42 increased the time of AMPA mEPSC interval, meaning that Aβ42 reduced 
AMPA mEPSC frequency. We found that the addition of insulin did not reduce 
AMPA mEPSC interval, suggesting that while Aβ42 could affect both 


















4.1 Aβ content in the ageing ApoEXAPP mice. 
 
The ApoE4 allele is the strongest genetic risk factor for AD (Holtzman et al, 
2012; Mahley & Rall, 2000; Mahley et al, 2006). While its mechanism is still 
currently unknown, it is certain that ApoE4 expression leads to earlier onset of 
the disease and rapid accumulation of Aβ plaques (Bales et al, 2009; Bien-Ly 
et al, 2011; Bien-Ly et al, 2012; Rodriguez et al, 2014; Tai et al, 2011; 
Youmans et al, 2012). In our characterization of Aβ42/40 ratios in the mouse 
models (Figure 2), we found that when co-expressed with APP, the expression 
of ApoE4 led to greater Aβ42/40 ratios in the brain as compared to the expression 
of ApoE3 or mouse ApoE. This increase in Aβ42/40 ratio became substantial 
when the mice aged to 52 weeks. In other words, the expression of ApoE4 led 
to earlier accumulation of Aβ42 and Aβ plaques (Figure 2, 3).  
 
Aβ42 is the predominant species found in plaques, and their oligomers were 
shown to be more neurotoxic than the Aβ40 species (Snyder et al, 1994; Stine et 
al, 2011). As memory decline in AD starts with difficulty to consolidate new 
memories, it was important for us to investigate the extent of Aβ plaque 
accumulation in the hippocampus (Mucke & Selkoe, 2012; Selkoe, 2002). In 
Figure 3A-D, we saw Aβ plaque accumulation occurring at an earlier time 
point, and in greater amounts in E4XAPP mice than in E3XAPP mice and APP 
mice. Our results, with the support of previous studies confirmed that the 
expression of ApoE4 led to earlier and greater Aβ42 levels and Aβ plaque 
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formation in the brain (Bales et al, 2009; Bien-Ly et al, 2011; Bien-Ly et al, 




4.2 ApoE isoform-specific effects on brain insulin signaling  
 
At 26 and 52 weeks, the basal expression of proteins within the insulin 
signaling pathway remained comparable among WT, APP, E3XAPP and 
E4XAPP mice brains (Figure 4A-D). However at 78 weeks, the levels of 
proteins within the insulin signaling pathway were markedly reduced in APP 
and E4XAPP mice brains (Figure 4E-F). We specifically chose to probe for 
IRS-1 Y608 and Akt S473 and T308. These proteins represented response to 
insulin stimulation and the resultant downstream signal amplification (Gual et 
al, 2005; Hemmings & Restuccia, 2012; Manning & Cantley, 2007; Myers et 
al, 1994). In previous studies, application of insulin in AD hippocampa 
formations did lead to increase in insulin receptor phosphorylation at Y1151 
(Talbot et al, 2012). However, the signaling cascade could not be effectively 
amplified as downstream IRS-1 Y608 phosphorylation was lacking (Talbot et 
al, 2012). Hence, the phosphorylation of IRS-1 Y608 and Akt S473 and T308 
provided a more stringent way of determining insulin signaling. While IRS-1 
Y608 phosphorylation showed the initiation of the downstream PI3K pathway, 
phosphorylated Akt at S473 and T308 indicated activation of effector proteins, 
thereby substantiating the occurrence of insulin signaling (Gual et al, 2005; 
Hemmings & Restuccia, 2012; Manning & Cantley, 2007; Myers et al, 1994).  
 
Although previous studies had reported that high Aβ levels led to insulin 
signaling impairment, we noted that these experiments were not done in the 
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presence of the human ApoE (Townsend et al, 2007; Zhao et al, 2004; Zhao et 
al, 2008). Therefore the data could not be convincingly translated to prove an 
association between AD and insulin signaling.  
 
To further our observation, we performed immunoblot analysis on post-
mortem human samples and probed for the same proteins. In Figure 5, we 
observed that downstream insulin signaling effector proteins were reduced in 
all AD cases regardless of ApoE isoform. As these samples represented the 
disease at its end-stage, we could affirm that insulin signaling was significantly 
reduced in AD (Craft & Watson, 2004; Frolich et al, 1998; Hoyer, 2002). 
Taken together, our data suggested that ApoE genotypes could modulate Aβ-




4.3 ApoE isoform differences in insulin receptor binding  
 
Aβ and insulin share a similar common recognition motif [RGFFYTPKT] for 
insulin receptor binding, and previous studies had shown that this resulted in 
Aβ competing with insulin for binding to the insulin receptor (Townsend et al, 
2007; Verdier et al, 2004; Xie et al, 2002; Zhao et al, 2008). Once Aβ was 
successfully bound to the insulin receptor, it prevented insulin action to elicit 
downstream response (Townsend et al, 2007; Verdier et al, 2004; Zhao et al, 
2008). However, the studies of Aβ binding to the insulin receptor were 
performed in the absence of the human ApoE, and the Aβ used was usually 
obtained from the condition media of APP transfected cell lines (Townsend et 
al, 2007).   
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Aβ was also capable of binding to ApoE (Beffert et al, 1998; Garai et al, 2014; 
LaDu et al, 1995; Munson et al, 2000; Sanan et al, 1994; Tai et al, 2013; Tai et 
al, 2014). In our mouse models, we showed an ApoE isoform dependent 
difference in ApoE binding to the insulin receptor and Aβ (Figure 6A). At all 
ages, ApoE3 was shown to associate more strongly to the insulin receptor. On 
the other hand, Aβ was detected to associate more to the ApoE4, regardless of 
age. At 78 weeks, we observed a slight increase in ApoE4 association with the 
insulin receptor. As the levels of Aβ in the E4XAPP mouse brain was very 
high by this time point, this slight increase might not be due to ApoE4 
associating with the insulin receptor, but the net effect of Aβ binding to the 
insulin receptor, which was detected while being pulled down. When we 
performed the same experiment using human samples, we observed that in 
control cases, there was always a greater association of the ApoE with the 
insulin receptor, and no detectable association with Aβ (Figure 6B). However, 
when comparing among AD cases, we observed that there was slightly greater 
association of the ApoE3 to the insulin receptor as compared to ApoE4. In 
addition, there was greater association of the ApoE4 to Aβ than compared to 
ApoE3.  
 
In view of these results, we could see that an association of the ApoE3 with the 
insulin receptor could have protected the mice from Aβ induced insulin 
signaling impairment. In our clinical samples, we showed that at the end-stage 
of the disease, both ApoE3 and ApoE4 showed reduced association to the 
insulin receptor. However, it maintained that the reduction was more apparent 
in the presence of the ApoE4 than in the ApoE3. Furthermore, we found that 
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the difference between 3/3AD and 3/3control cases was that the ApoE in 
control cases associated more to the insulin receptor. Although previous 
finding showed that Aβ could bind to the insulin receptor, we needed to 
consider a few differences. Firstly, the experiments were not conducted in the 
presence of the human ApoE. Secondly, the Aβ added were obtained from the 
culture media of cells lines over-expressing APP, and the Aβ species present 
were mostly oligomers. In these studies, the insulin receptor was exposed only 
acutely to the oligomeric Aβ, whereas in our study, the insulin receptor was 
constantly exposed to endogenously produced Aβ, across time. As we did not 
detect an association between the insulin receptor and Aβ in E4XAPP mice, it 
was possible that while some Aβ could have bonded to the insulin receptor, 
thereby inhibiting downstream insulin signaling (Figure 8, 9), the ApoE4 itself 
might have bonded the other free Aβ in the brain and stabilizing them to form 
fibrils and eventually plaques (Figure 3, 7). 
 
Given that there was more Aβ42 in the presence of ApoE4, we wanted to know 
if it was an intrinsic characteristic difference between the ApoE isoforms that 
allowed it to associate differently with the insulin receptor, or were the results 
observed in Figure 6 attributed to the different levels of Aβ present in the 
samples. As such, we set up a sandwich ELISA and showed that ApoE3 
associated more with the insulin receptor, regardless of Aβ42 concentrations. On 
the other hand, ApoE4 did not associate well with the insulin receptor (Figure 
7A, C). However, when we looked at ApoE association with Aβ42, we observed 
that while both ApoE3 and ApoE4 bound to Aβ42 equally at lower levels (0-
	  82 
30nM), ApoE4 bound Aβ42 more at higher concentrations (Figure 7B). This 
showed that at every single concentration of Aβ42, the ApoE3 associated more 
with the insulin receptor, and this could have prevented the detrimental effects 
of Aβ on the insulin signaling pathway. On the other hand, ApoE4 preference 
to Aβ42 and the resultant plaque formation could have left the insulin receptor 
unprotected for unbound Aβ42 to exert its effects on.  
 
While other groups have reported that ApoE3 bonded Aβ42 more (LaDu et al, 
1995; Munson et al, 2000; Tai et al, 2013; Tai et al, 2014), it was crucial to 
highlight the important differences. Firstly, these groups used HEK transfected 
ApoE, and collected ApoE from the culture medium for experiments (LaDu et 
al, 1995; Munson et al, 2000; Tai et al, 2013; Tai et al, 2014). In our study, the 
ApoE was produced in targeted knock-in mice, where ApoE was expressed in a 
physiologically relevant way. In addition, other groups have shown that it was 
ApoE4 that bonded more to Aβ25-35, which was the biologically active site of 
Aβ, and an overlapping region within Aβ42 (Beffert et al, 1998). Taken 
together, our results showed a novel finding that the differences in association 
of ApoE3 and ApoE4 to the insulin receptor could influence the effects of Aβ 




4.4 Co-Expression of ApoE4 and Aβ42 impaired response to 
insulin stimulation 
 
Given that insulin response in the E4XAPP mouse hippocampus was 
attenuated at a young age, we asked if ApoE4 alone could cause insulin 
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signaling impairment.  To investigate this, we cultured primary hippocampal 
neurons from our ApoE3 and ApoE4 knock-in mice, and subjected them to 
acute insulin stimulation with or without Aβ42 pre-treatment. Interestingly, the 
expression of ApoE4 alone did not inhibit response to insulin, and the 
consequent increase in IRS-1 and Akt phosphorylation were comparable to that 
of ApoE3 neurons (Figure 8). However, in the presence of Aβ42, insulin failed 
to elicit a downstream response in ApoE4 hippocampal neurons. In contrast, 
Aβ42 pre-treated ApoE3 hippocampal neurons remained sensitive to insulin 
stimulation. Hence, we established that response to insulin stimulation was 
detriment in ApoE4 neurons only with the co-presence of Aβ42. Assimilating 
results from our previous experiments, we could see that in the presence of the 
ApoE4, the threshold for Aβ42 induced deficits on insulin signaling seemed to 
be reduced. This meant that for the same levels of Aβ42, insulin sensitivity was 
greatly reduced when in the presence of ApoE4 (Figure 8, 9). As previously 
mentioned, a functional insulin signaling was crucial for neuronal survival, and 
learning and memory. We demonstrated again, that the expression of ApoE4 
predisposed one to earlier onset of AD possibly because it could impair insulin 
signaling even in the absence of abnormal Aβ accumulation.  
 
In 2012, Talbot and his colleagues demonstrated that insulin response was 
attenuated in the hippocampal formation of AD cases. In light of this result, we 
wondered if ApoE isoforms played a part in modulating the response to insulin 
treatment. Using our mouse models, we starved and stimulated the mouse 
hippocampus at 26, 52 and 78 weeks, allowing us to capture the response of 
the mouse hippocampus to insulin at various stages of Aβ plaque formation. In 
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Figure 9A, we showed that insulin signaling deficiency in the E4XAPP 
hippocampus was an early event. As the E4XAPP mice aged, insulin response 
in the hippocampus remained impaired. On the other hand, the hippocampus of 
the E3XAPP mouse was distinctly stimulated by insulin. Although the fold 
change in Akt activation in E3XAPP mouse hippocampus was reduced as the 
mouse aged (Figure 9A-C), Akt activation at 78 weeks was still significant. In 
APP mice, the start of insulin signaling deficits occurred later than E4XAPP 
mice but earlier than E3XAPP mice. As APP mice represented the effects of 
Aβ in the absence of the human ApoE, we could conclude that the expression 
of ApoE4 hastened the age where insulin signaling response was attenuated. 
Interestingly, insulin impairment in E4XAPP mouse hippocampus was already 
observed even at low levels of Aβ plaques. As opposed to ApoE3 expression, 
this observation suggested that ApoE4 and APP co-expression was key to 
undermining insulin stimulation. As a functional insulin signaling pathway was 
shown to be important for learning and memory (Nistico et al, 2012; Reger et 
al, 2006; Reger et al, 2008; Townsend et al, 2007; Zhao & Alkon, 2001), and 
that synaptic loss started in patients prior to gross Aβ plaque load (Selkoe, 
2002), our data further suggested that the earlier onset of memory impairment 
observed in ApoE4 carriers could be due to the lack of an operative insulin 
response, given that this phenomenon was upstream of Aβ induced deficits. 
While ApoE3 was not known to be neuroprotective, our results suggested that 
its expression could have provided some form of resilience to the devastating 
effects of Aβ. In summary, this showed that the ApoE4 could lead to an earlier 
impairment of brain insulin signaling, thereby contributing to an earlier onset 
of AD. 
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4.5 Spatial memory impairment in E4XAPP mice was an early 
event 
 
To investigate if the loss of insulin sensitivity even in the absence of extensive 
Aβ plaques was affecting the memory of E4XAPP mice, we used an eight-arm 
Radial Maze to test the ability of our mice in their ability to consolidate 
memory and recall them. The hippocampus was the site for these tasks. Our 
results showed that the E4XAPP mice showed short-term and long-term 
memory deficits at 26 weeks, which corresponded to the time where the 
hippocampus showed impaired response to insulin stimulation (Figure 9, 10). 
Although the E3XAPP mice did exhibit poorer long-term memory performance 
at 78 weeks when compared to WT, this result was expected given the fact that 
Aβ plaques had accumulated in the E3XAPP mice by then. However, this data 
showed three important points. Firstly, insulin sensitivity was important for 
memory consolidation and preservation of the short-term memory. Secondly, 
the co-expression of ApoE4 with APP, even when Aβ plaques were scanty, 
was capable of causing short-term memory deficits. Thirdly, the expression of 
ApoE3 in E3XAPP mice provided some form of plasticity that cushioned the 
onslaught of Aβ on insulin sensitivity and memory. These observations were in 
line with clinical reports showing that insulin clamping helped non-ApoE4 AD 
patients perform better in recalling stories that were told to them within a day 










4.6 Insulin-induced AMPA insertion was ApoE isoform 
dependent  
 
We had shown that insulin sensitivity was required for learning and 
preservation of short-term memory in our mouse models. Using our in vitro 
model of ApoE3 and ApoE4 hippocampal neurons, we wanted to understand 
how insulin sensitivity could affect learning and memory. We first observed 
that under non-permeabilizing conditions, insulin sensitivity led to an increase 
in new GluR1 subunits being inserted into the postsynaptic membrane and 
Aβ42 reduced the number of AMPA receptors that were inserted (Figure 11). 
We repeated work that was published by others, and showed further that this 
insulin-sensitivity driven GluR1 insertion was dependent on the type of ApoE 
isoform expressed in the presence of Aβ42. To show that insulin affected 
AMPA and not NMDA receptors in learning and memory, we simulated LTP 
in our hippocampal neurons using glycine-induced LTP. We first observed that 
addition of insulin did not affect NMDA mEPSC amplitude (Figure 12). This 
showed that the NMDA receptor was not a target of insulin stimulation. On the 
other hand, insulin application led to an increase in AMPA mEPSC amplitude 
but not frequency, in both ApoE3 and ApoE4 neurons (Figure 12, 13). This 
meant that insulin could affect AMPA postsynaptically by either increasing the 
number of AMPA receptor inserted into the membrane, or insulin could 
increase channel conductance. In the presence of Aβ42, both ApoE3 and ApoE4 
showed reduced AMPA mEPSC frequency and amplitude. Aβ42 reduced 
glutamate release from the presynaptic neuron and also impaired AMPA 
receptor postsynaptically (Figure 13). When stimulated with insulin, mEPSC 
frequency of Aβ42 pre-treated ApoE3 and ApoE4 neurons was not rescued. This 
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meant that insulin did not affect presynaptic neuron release mechanisms and 
could not rescue Aβ42 induced impairment at the presynaptic neuron. However, 
when we compared the effects of insulin on AMPA mEPSC amplitude between 
Aβ42 pre-treated ApoE3 and ApoE4 neurons, we observed a significant 
difference. The AMPA mEPSC amplitude of the ApoE3 neurons was 
increased, comparable to its non-treated group. Yet in Aβ42 pre-treated ApoE4 
neurons, insulin treatment could not rescue AMPA mEPSC amplitude. 
 
While other groups have shown that an AMPA insertion in the presence of 
glycine was PI3K dependent, the experiments were not done in the presence of 
the human ApoE, and thus not easily translated into explaining a disease 
condition, such as AD (Chan et al, 2011; Chang et al, 2006; Man et al, 2003; 
Passafaro et al, 2001). In the presence of glycine, PI3K increased AMPA 
exocytosis via a PIKE-GRIP association (Chan et al, 2011). In our study, we 
showed that 2nM of insulin activated the PI3K-Akt pathway in hippocampal 
neurons (Figure 8). Hence, insulin stimulation enhanced AMPA receptor 
insertion as PI3K was continuously activated (Manning & Cantley, 2007). In 
our study, we furthered this observation. We showed that insulin sensitivity 
increased AMPA receptor insertion whereas Aβ42 impaired it. We also showed 
that this was ApoE isoform specific. In the presence of Aβ42, the expression of 
ApoE4 rendered neurons to become insensitive to insulin stimulation. This 
reduced AMPA insertion in response to glycine. Although some have argued 
that insulin application led to AMPA removal from the membrane via 
phosphorylation of tyrosine residue on the C-terminal tail of GluR2, we noted 
that the concentration of insulin added in these experiments were more than a 
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thousand times higher than what was physiological. When the concentration of 
insulin was reduced to nanomolar ranges, insulin stimulation was shown to 
increase GluR1 exocytosis (Ahmadian et al, 2004; Lin et al, 2000; Passafaro et 
al, 2001). Furthermore, in Aβ42 pre-incubated slices, insulin stimulated LTP 
(Townsend et al, 2007). In sum, we showed that insulin stimulation increased 
LTP by increasing the number of postsynaptic AMPA receptor, and the rescue 





















Taken together, this project teased out a mechanistic explanation as to why 
ApoE4 expression could lead to an earlier onset of AD. Firstly, we showed that 
insulin insensitivity in the hippocampus corresponded well to the onset of 
memory impairment, and this insulin resistance could lower the threshold of 
Aβ42 induced damage on the neurons. Secondly, we showed that insulin 
response increased AMPA insertion under chemical LTP conditions, and was 
required to protect against Aβ42 induced reduction of AMPA insertion. As such, 
our project showed immense clinical implications. As insulin signaling 
impairment and memory decline was an early event, patients could be screened 
and categorized according to their ApoE groups. Preventive therapies such as 
increasing insulin sensitivity or ApoE-targeted therapeutics could be performed 
at a much earlier time. This could retard AD progression or and provide a 










We showed an ApoE-isoform dependent effect on insulin signaling, which in 
turned affected AMPA GluR1 subunit insertion in the presence of Aβ42. In 
light of this, we propose to attempt to convert ApoE4 to an “ApoE3-like” 
structure; to understand if the structural difference between ApoE3 and ApoE4 
was a cause for this difference. The mutation of Arg61 residue to Thr61 
(R61T-ApoE) was reported to convert ApoE4 to become more “ApoE3-like” 
(Mahley & Huang, 2012). We could employ this strategy by transducing 
R61T-ApoE into our ApoE-KO hippocampal neurons. From there, we could 
repeat our electrophysiological and biochemical experiments. If structure was a 
determining cause of ApoE4 dependent insulin signaling deficiency in the 
presence of Aβ42, R61T-ApoE would rescue these observations. This could 
also be a basis for ApoE-structure therapeutics for preventing ApoE4 induced 
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